News Releases

Dec 03, 2018
Sangamo Announces Completion Of TxCell Acquisition
RICHMOND, Calif. and VALBONNE, France , Dec. 3, 2018 /PRNewswire/ --  Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced the completion of the acquisition of TxCell, SA . TxCell is now a subsidiary of Sangamo and has been delisted from the French stock market.
Additional Formats
Nov 08, 2018
Sangamo Therapeutics Reports Third Quarter 2018 Financial Results
Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time RICHMOND, Calif. , Nov. 8, 2018 /PRNewswire/ --  Sangamo Therapeutics, Inc. (NASDAQ: SGMO) today reported third quarter 2018 financial results and recent business highlights. "I'm pleased with our continued execution toward our vision
Additional Formats
Sep 05, 2018
Sangamo Announces 16 Week Clinical Results Including Reductions In Glycosaminoglycans In Phase 1/2 Trial Evaluating SB-913, A Zinc Finger Nuclease Genome Editing Treatment For MPS II (Hunter Syndrome)

SSIEM presentation included early data from Cohorts 1 (low dose) and 2 (mid dose); enrollment of Cohort 3 (high dose, 5x the mid dose) was recently completed Total urinary GAGs declined by 51%, dermatan sulfate by 32%, and heparan sulfate by 61% in Cohort 2 at 16 weeks SB-913 has been generally

Additional Formats
Displaying 1 - 10 of 43